A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial

Conflicts of interest
P.C.M.v.d.K. with Abbott, Allmiral, Barrier, Cellgene, Centocor, Galderma, LEO Pharma, Pfizer, Serono, UCB Pharma and Wyeth. V.H. is an employee of LEO Pharma. This study was sponsored by LEO Pharma.

Data collection took place at all the above institutions. A list of participating investigators is provided at the end of this article.

Read the full text

About

PDF

Tools

Share a link

Email
Wechat
Bluesky

Summary

Background There is a need for new treatments for scalp psoriasis, as many topical treatments are cosmetically unacceptable and difficult to apply, resulting in poor compliance.

Objectives To compare the efficacy and safety of a new, once-daily, two-compound scalp formulation (Xamiol^®; LEO Pharma A/S, Ballerup, Denmark) containing calcipotriol 50 μg g⁻¹ plus betamethasone 0·5 mg g⁻¹ (as dipropionate), with the active ingredients as single compounds in the same vehicle.

Methods This 8-week, multicentre, double-blind, parallel-group study, randomized adult patients with scalp psoriasis involving > 10% of the scalp to the two-compound scalp formulation (n = 568), betamethasone dipropionate 0·5 mg g⁻¹ (n = 563), or calcipotriol 50 μg g⁻¹ (n = 286). The primary efficacy measure was the proportion of patients with ‘absence of disease’ or ‘very mild disease’ according to investigators’ assessments at week 8.

Results The proportion of patients with ‘absence of disease’ or ‘very mild disease’ at week 8 was significantly higher in the two-compound group (68·4%) than the betamethasone dipropionate (61·0%, P = 0·0079) or calcipotriol (43·4%, P < 0·0001) groups. The proportion of patients rating their scalp psoriasis as ‘clear’ or ‘almost clear’ was significantly higher for the two-compound scalp formulation (69·6%) than for betamethasone dipropionate (59·9%, P = 0·0006) or calcipotriol (44·7%, P < 0·0001). The incidence of lesional/perilesional adverse events was lower in the two-compound and betamethasone dipropionate groups than the calcipotriol group.

Conclusions The two-compound scalp formulation was well tolerated and more effective in the treatment of scalp psoriasis than either of its individual components in the same vehicle.

References

1 Brandrup F, Green A. The prevalence of psoriasis in Denmark. Acta Derm Venereol (Stockh) 1981; 61: 344–6.
PubMed Web of Science® Google Scholar
2 Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica 1974; 148: 1–18.
10.1159/000251595
CAS PubMed Web of Science® Google Scholar
3 Poyner TF, Fell PJ. A survey of patients with plaque psoriasis who had not consulted their doctor in the past year. Br J Clin Res 1995; 6: 201–7.
Google Scholar
4 Van De Kerkhof PCM, Steegers-Theunissen RPM, Kuipers MV. Evaluation of topical drug treatment in psoriasis. Dermatology 1998; 197: 31–6.
10.1159/000017972
CAS PubMed Web of Science® Google Scholar
5 Farber EM, Bright RD, Nall ML. Psoriasis. A questionnaire survey of 2,144 patients. Arch Dermatol 1968; 98: 248–59.
PubMed Web of Science® Google Scholar
6 Van De Kerkhof PCM, De Hoop D, De Korte J, Kuipers MV. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology 1998; 197: 326–34.
10.1159/000018026
CAS PubMed Web of Science® Google Scholar
7 Feldman SR, Housman TS. Patients’ vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol 2003; 4: 221–4.
10.2165/00128071-200304040-00001
PubMed Web of Science® Google Scholar
8 Berth-Jones J, Dodd WA, Ganpule M et al. A multi-centre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol 1992; 127: 266–71.
10.1111/j.1365-2133.1992.tb00126.x
PubMed Web of Science® Google Scholar
9 Tham SN, Lim KC, Cheong WK. A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis. Br J Dermatol 1994; 131: 673–7.
10.1111/j.1365-2133.1994.tb04981.x
PubMed Web of Science® Google Scholar
10 Cunliffe WJ, Berth-Jones J, Claudy A et al. Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol 1992; 26: 736–43.
10.1016/0190-9622(92)70103-M
CAS PubMed Web of Science® Google Scholar
11 Kragballe K, Gjertsen BT, De Hoop D et al. Double-blind right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991; 337: 193–6.
10.1016/0140-6736(91)92157-W
CAS PubMed Web of Science® Google Scholar
12 Ramsay CA, Berth-Jones J, Brundin G et al. Long-term use of topical calcipotriol in chronic plaque psoriasis. Dermatology 1994; 189: 260–4.
10.1159/000246851
PubMed Web of Science® Google Scholar
13 Poyner T, Hughes IW, Dass BK, Adnitt PI. Long-term treatment of chronic plaque psoriasis with calcipotriol. J Dermatolog Treat 1993; 4: 173–7.
10.3109/09546639309089517
Google Scholar
14 Ellis JP, Griffiths WAD, Klaber MR. Long-term treatment of chronic plaque psoriasis with calcipotriol ointment in patients unresponsive to short contact dithranol. Eur J Clin Res 1995; 7: 247–57.
Google Scholar
15 Green C, Ganpule M, Harris D et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. Br J Dermatol 1994; 130: 483–7.
10.1111/j.1365-2133.1994.tb03382.x
CAS PubMed Web of Science® Google Scholar
16 Thaçi D, Daiber W, Boehncke WH, Kaufmann R. Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3,396 patients. Dermatology 2001; 203: 153–6.
10.1159/000051731
CAS PubMed Web of Science® Google Scholar
17 Barnes L, Altmeyer P, Forstrom L, Stenstrom MH. Long-term treatment of psoriasis with calcipotriol scalp solution and cream. Eur J Dermatol 2000; 10: 199–204.
CAS PubMed Web of Science® Google Scholar
18 Kragballe K, Austad J, Barnes L et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol 2006; 154: 1155–60.
10.1111/j.1365-2133.2006.07236.x
CAS PubMed Web of Science® Google Scholar
19 Kragballe K, Van De Kerkhof PCM. Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 39–44.
10.1111/j.1468-3083.2005.01343.x
CAS PubMed Web of Science® Google Scholar
20 Buckley C, Hoffmann V, Shapiro J et al. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology 2008; 217: 107–13.
10.1159/000130425
CAS PubMed Web of Science® Google Scholar
21 Papp KA, Guenther L, Boyden B et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003; 48: 48–54.
10.1067/mjd.2003.130
PubMed Web of Science® Google Scholar
22 Douglas WS, Poulin Y, Decroix J et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol (Stockh) 2002; 82: 131–5.
10.1080/00015550252948194
CAS PubMed Web of Science® Google Scholar
23 Kaufmann R, Bibby AJ, Bissonnette R et al. A new calcipotriol/betamethasone formulation is a highly effective once-daily treatment for psoriasis vulgaris. Dermatology 2002; 205: 389–93.
10.1159/000066440
CAS PubMed Web of Science® Google Scholar
24 Guenther L, Cambazard F, Van De Kerkhof PCM et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002; 147: 316–23.
10.1046/j.1365-2133.2002.04967.x
CAS PubMed Web of Science® Google Scholar
25 Charakida A, Dadzie O, Teixeira F et al. Calcipotriol/betamethasone dipropionate for the treatment of psoriasis. Expert Opin Pharmacother 2006; 7: 597–606.
10.1517/14656566.7.5.597
CAS PubMed Web of Science® Google Scholar
26 Van De Kerkhof PCM, Franssen MEJ. Psoriasis of the scalp: diagnosis and management. Am J Clin Dermatol 2001; 2: 159–65.
10.2165/00128071-200102030-00005
CAS PubMed Google Scholar
27 Van Der Vleuten CJM, Van De Kerkhof PCM. Management of scalp psoriasis. Guidelines for corticosteroid use in combination treatment. Drugs 2001; 61: 1593–8.
10.2165/00003495-200161110-00006
CAS PubMed Web of Science® Google Scholar
28 Koo J. Vitamin D and scalp psoriasis. Cutis 2002; 70 (Suppl.): 21–4.
PubMed Web of Science® Google Scholar
29 Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004; 140: 408–14.
10.1001/archderm.140.4.408
PubMed Web of Science® Google Scholar

Citing Literature

Volume160, Issue1

January 2009

Pages 170-176

A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial

Summary

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial

Summary

References

Citing Literature

References

Related

Information